Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis

Renal Insufficiency, Chronic Clinical Trial

Official title: Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis: A Multicentre Prospective, Randomized, Double-blind and Imitation, Positive-drug Parallel Controlled Clinical Trail

Status Recruiting

Clinical Trial Summary

This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.

Clinical Trial Description

Chronic kidney disease is a common disease that affects health seriously. In some regions of China, the morbidity of this kind of disease is as high as 10.8%. Primary glomerulopathy is one of the pathogenesis of chronic kidney disease, which occupied 50%-60%. However, at present, there is still a lack of effective means for the treatment of primary glomerulonephritis in CKD stage 3. Huaiqihuang Granule is a kind of Chinese herbal medicine compound preparation, Previous researches showed that Huaiqihuang has a comprehensive effect on primary glomerulonephritis. In this study, there were about 40 first-class hospitals participating in. We planned to enroll 466 participants, who will be randomly divided into the Huaiqihuang Granule group (experimental group) and the Valsartan group (control group). All participants will take medication for 48 weeks, and investigators will follow up participates at weeks 0, 8,16, 24, 32, 40, 48. ;

Related Conditions & MeSH terms

• Glomerulonephritis
• Renal Insufficiency
• Renal Insufficiency, Chronic

• NCT number: NCT04263922
• Study type: Interventional
• Source: The First Affiliated Hospital of Dalian Medical University
• Contact: Hongli Lin, MD
• Phone: +86-13332268576
• Email: linhongli@vip.163.com
• Status: Recruiting
• Phase: Phase 4
• Start date: June 30, 2020
• Completion date: March 30, 2026